Replies to post #213514 on Biotech Values

[dangerM]

... definitely, somehow some suspicion is sneaking in on my side that they "prepared" for the Mystic (1L) failure. Tje trials for a Imfinzi/durvalumab + chemo combo are quite young (if I am right they were anounced at the ASCO 2017 investor event and accordingly run into 2019/2020):

https://clinicaltrials.gov/ct2/show/NCT03164616 (POSEIDON)

https://clinicaltrials.gov/ct2/show/NCT03043872 (CASPIAN)

Thanks for the comment!

dM

[P.S./EDIT: from the ESMO press release ... well

“There is evidence that synergy between radiotherapy and immunotherapy, such programmed death-ligand 1 (PD-L1) inhibitors, could increase the probability of response,” said first author Dr Luis Paz-Ares, chair, Medical Oncology Department, Hospital Universitario Doce de Octubre, Madrid, Spain. “We therefore explored the impact of PD-L1 inhibition after standard chemoradiation treatment.”

http://esmo.org/Press-Office/Press-Releases/Durvalumab-Improves-Progression-free-Survival-in-Stage-III-Lung-Cancer?hit=ehp

]